Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.xcrm.2021.100228 http://scihub22266oqcxt.onion/10.1016/j.xcrm.2021.100228 33748788!7955929!33748788     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Rep+Med 2021 ; 2 (4): 100228 Nephropedia Template TP {{tp|p=33748788|t=2021. Long-term persistence of RBD(+) memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection |pdf=|usr=}}{{33748788}} gab.com Text Long-term persistence of RBD(+) memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection JO: Cell Rep Med http://www.kidney.de/pget.php?&tw=1&pmid=33748788 #FOAvip Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2 receptor-binding domain (RBD) for up to 6 months after infection. While antibody titers are maintained, approximately 13% of the cohort's neutralizing responses return to background. However, encouragingly, in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralizing capacity from these memory B cells. Overall, our study suggests that the loss of neutralizing antibodies in plasma may be countered by the maintenance of neutralizing capacity in the memory B cell repertoire. Twit Text FOAVip Long-term persistence of RBD(+) memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection ????Cell Rep Med http://www.kidney.de/pget.php?&tw=1&pmid=33748788 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33748788 #FOAvip English Wikipedia <ref>{{Cite pmid|33748788}}</ref> Long-term persistence of RBD(+) memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection #MMPMID33748788 Abayasingam A; Balachandran H; Agapiou D; Hammoud M; Rodrigo C; Keoshkerian E; Li H; Brasher NA; Christ D; Rouet R; Burnet D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Stella AO; Fichter C; Brilot F; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Tea F; Pilli D; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA Cell Rep Med 2021[Apr]; 2 (4): 100228 PMID33748788show ga Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2 receptor-binding domain (RBD) for up to 6 months after infection. While antibody titers are maintained, approximately 13% of the cohort's neutralizing responses return to background. However, encouragingly, in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralizing capacity from these memory B cells. Overall, our study suggests that the loss of neutralizing antibodies in plasma may be countered by the maintenance of neutralizing capacity in the memory B cell repertoire. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Neutralizing/*blood/immunology[MESH] |Asymptomatic Diseases[MESH] |COVID-19/immunology/*pathology/virology[MESH] |Female[MESH] |Humans[MESH] |Limit of Detection[MESH] |Male[MESH] |Memory B Cells/*metabolism[MESH] |Middle Aged[MESH] |Neutralization Tests[MESH] |Protein Domains/immunology[MESH] |SARS-CoV-2/isolation & purification/*metabolism[MESH] |Severity of Illness Index[MESH] |Spike Glycoprotein, Coronavirus/*chemistry/immunology/metabolism[MESH] |Time Factors[MESH]Long-term persistence of RBD(+) memory B cells encoding neutralizing a(epmc).pdf DeepDyve Pubget Overpricing